--- title: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene nct_id: NCT07069699 overall_status: RECRUITING phase: PHASE1, PHASE2 sponsor: National Cancer Institute (NCI) study_type: INTERVENTIONAL primary_condition: Burkitt Lymphoma countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07069699.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07069699" ct_last_update_post_date: 2026-04-28 last_seen_at: "2026-05-12T06:36:56.485Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene **Official Title:** Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma **NCT ID:** [NCT07069699](https://clinicaltrials.gov/study/NCT07069699) ## Key Facts - **Status:** RECRUITING - **Phase:** PHASE1, PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 50 - **Lead Sponsor:** National Cancer Institute (NCI) - **Conditions:** Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements - **Start Date:** 2026-10-13 - **Completion Date:** 2030-01-31 - **CT.gov Last Update:** 2026-04-28 ## Brief Summary This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma. ## Detailed Description PRIMARY OBJECTIVES: I. To define dose limiting toxicity (DLT). (Phase 1) II. To assess toxicity profile. (Phase 1) III. To determine the recommended phase 2 dose (RP2D). (Phase 1) IV. To perform pharmacokinetic (PK) studies. (Phase 1) V. To examine the effect of CX-5461 (Pidnarulex) on gene expression profile of MYC aberrant lymphomas. (Phase 1) VI. To determine the objective response rate (ORR) (complete response \[CR\] and partial response \[PR\]). (Phase 2) SECONDARY OBJECTIVE: I. To observe and record anti-tumor activity. (Phase 1 and 2) EXPLORATORY OBJECTIVES: I. To determine the mechanisms of response and resistance using circulating tumor deoxyribonucleic acid (ctDNA). (Phase 1 and 2) II. To observe cerebral spinal fluid (CSF) distribution of CX-5461 (Pidnarulex). (Phase 1 and 2) OUTLINE: This is a phase 1 dose-escalation study of CX-5461 followed by a phase 2 study. Patients receive CX-5461 intravenously (IV) over 60 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture with cerebrospinal fluid (CSF) collection on study and positron emission tomography (PET) scan/computed tomography (CT) scan, tumor biopsy, and blood sample collection throughout the study. After completion of study treatment, patients are followed up at 30 days, every 3-4 months for the first 2 years, and every 6 months for years 3-5. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Patients must have one of the following subtypes of aggressive B-cell non-Hodgkin lymphomas: double-expressor lymphoma (DEL), high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangement, or Burkitt lymphoma (BL). Eligible patients must have received at least two prior lines of treatment for diffuse large B-cell lymphoma (DLBCL) or at least one prior line of therapy for Burkitt Lymphoma and must have disease for which no standard curative or palliative treatment options exist or remain effective (Quin et al., 2016) * Age ≥ 18 years. Because no dosing or adverse event (AE) data are currently available on the use of CX-5461 (Pidnarulex) in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%). ECOG 3 is allowed if directly related to lymphoma per treating provider * Absolute neutrophil count ≥ 1,000/mcL * Platelets ≥ 50,000/mcL * Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN) * Patients with documented Gilbert's syndrome may be included if total bilirubin is ≤ 3 × ULN and direct bilirubin is within normal limits * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 × institutional upper limit of normal (ULN) * Glomerular filtration rate (GFR) ≥ 60 mL/min/, calculated by multiplying the estimated (e)GFR (mL/min/1.73 m\^2) by the individual's body surface area (BSA, calculated using an accepted formula) and dividing by 1.73 m\^2 * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better * Patients with cytopenia related to abnormal bone marrow function in the setting of bone marrow involvement with lymphoma or post chimeric antigen receptor (CAR) T-cell are allowed to enroll if deemed safe by treating provider * Patients without clinical evidence of central nervous system (CNS) lymphoma * The effects of CX-5461 (Pidnarulex) on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) 14 days prior to study entry and for the duration of study participation and for at least 6 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women should not breastfeed while taking CX-5461 (Pidnarulex) and for 6 months after cessation of treatment. Men treated or enrolled on this protocol must also agree to use adequate contraception 14 days prior to the study, for the duration of study participation, and 6 months after completion of CX-5461 (Pidnarulex) administration. Women of childbearing age should not donate egg(s) and men should not donate sperm for the duration of study participation and 6 months after completion of the last dose CX-5461 (Pidnarulex) * Willingness to provide blood and biopsy samples for research purposes * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients must have recovered from clinically significant adverse events (AEs) of their most recent cancer immunotherapy to grade 1 or less (with the exception for alopecia or lymphopenia) * Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of CX-5461 (Pidnarulex) will be determined based on their potential to interact with the CYP3A4 isozyme. Specifically, subjects taking strong CYP3A4 inhibitors or strong CYP3A4 inducers will be excluded from participation in the trial. For medications or substances not listed, or in cases of uncertainty, the Principal Investigator may consult with a medical expert or a pharmacologist to make an informed decision regarding eligibility * Patients with a baseline corrected QT (QTc) interval \> 480 msec * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to CX-5461 (Pidnarulex) * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous * Pregnant women are excluded from this study because CX-5461 (Pidnarulex) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with CX-5461 (Pidnarulex), breastfeeding should be discontinued if the mother is treated with CX-5461 (Pidnarulex) ``` ## Arms - **Treatment (CX-5461)** (EXPERIMENTAL) — Patients receive CX-5461 IV over 60 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture with CSF collection on study and PET scan/CT scan, tumor biopsy, and blood sample collection throughout the study. ## Interventions - **Biopsy Procedure** (PROCEDURE) — Undergo tumor biopsy - **Biospecimen Collection** (PROCEDURE) — Undergo CSF and blood sample collection - **Computed Tomography** (PROCEDURE) — Undergo PET/CT scan - **Lumbar Puncture** (PROCEDURE) — Undergo lumbar puncture - **Pidnarulex** (DRUG) — Given IV - **Positron Emission Tomography** (PROCEDURE) — Undergo PET/CT scan ## Primary Outcomes - **Incidence of adverse events (Phase 1)** _(time frame: Up to 30 days after last dose of study treatment)_ — Assessed by the Common Terminology Criteria for Adverse Events version 5. Safety will be summarized overall, by actual dose level in Phase 1b. - **Recommended phase 2 dose (RP2D) (Phase 1)** _(time frame: Up to 5 years)_ - **Pharmacokinetic (PK) levels (Phase 1)** _(time frame: At cycle (C) 1 day (D) 8 at pre-dose, end of infusion, and 2 hours (hrs) post-dose; on C1D9 at 24 hrs post C1D8 infusion; on C1D10 at 48 hrs post C1D8 infusion; on C1D11 at 72 hrs post C1D8 infusion; and on C1D15 at 167 hrs post C1D8 infusion)_ — Assessed using Liquid Chromatography Mass Spectrometry (LC-MS). - **Gene expression (Phase 1)** _(time frame: At baseline, C1D9 or C1D10 (within 24-48 hrs of C1D8 dosing),and at progression)_ — Assessed by ribonucleic acid sequencing complemented by whole exome sequencing using an average absolute log2 fold change relative to baseline with a significance threshold of p \< 0.05. - **Overall response rate (Phase 2)** _(time frame: Up to 5 years)_ — Assessed using standard radiographic criteria according to Lugano criteria. Phase 2 results will be reported at the RP2D. ## Secondary Outcomes - **Response to therapy (Phase 1 and 2)** _(time frame: Up to 5 years)_ ## Locations (4) - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States — _RECRUITING_ - UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States — _RECRUITING_ - University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States — _RECRUITING_ - University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.uci health - chao family comprehensive cancer center and ambulatory care|irvine|california|united states` — added _(2026-05-12)_ - `locations.uc irvine health/chao family comprehensive cancer center|orange|california|united states` — added _(2026-05-12)_ - `locations.university of oklahoma health sciences center|oklahoma city|oklahoma|united states` — added _(2026-05-12)_ - `locations.university of pittsburgh cancer institute (upci)|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07069699.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07069699* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*